{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_6821946_B2","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"040-289-614-446-471","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8907,"type":"PATENT","title":"Univ College London Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":4836,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8222,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search applicants and owners= \"Univ College London\", \" UCL\", \" University College of London\", \"Univ* Col* Lond*\", \"College university London\", \"College univ London',
Search applicants and owners= \"Univ College London\", \" UCL\", \" University College of London\", \"Univ* Col* Lond*\", \"College university London\", \"College univ London',
said treatment comprising administering to a subject comprising said nerve an effective non-toxic amount of an MGF (mechano-growth factor) polypeptide having the ability to reduce motoneurone loss by 20% or greater in response to nerve avulsion,
said administration comprising delivering said MGF polypeptide to the site of said damage;
said MGF polypeptide comprising at least one sequence selected from the group consisting of:
(a) an amino acid sequence comprising a sequence encoded by exons 3-4-5-6 of a mammalian MGF; and
(b) an amino acid sequence having 80% or greater sequence identity, over the sequence encoded by exons 3-4-5-6, to an amino acid sequence of (a)."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["A method of claim 1 wherein said MGF polypeptide is administered to said subject at a site of said damaged nerve by means of a conduit placed around the damaged nerve."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["A method of claim 2 wherein the conduit comprises Poly-3-hydroxy-butyrate (PHB)."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["A method of claim 2 wherein said conduit comprises at least one of collagen and silicone."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["A method of claim 2 wherein the damaged nerve was severed."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["A method of claim 1 wherein the damaged nerve was severed."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["A method of claim 1 wherein said MGF polypeptide has the ability to reduce motoneurone loss by 50% or greater in response to nerve avulsion."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["A method of claim 1 wherein said MGF polypeptide has the ability to reduce motoneurone loss by 80% or greater in response to nerve avulsion."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["A method of claim 1 wherein the MGF polypeptide is unglycosylated."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["A method of claim 1 wherein said MGF polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4 and 6."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["A method of claim 1 wherein said MGF polypeptide comprises an amino acid sequence having 90% or greater sequence identity, over the sequence encoded by exons 3-4-5-6, to an amino acid sequence of (a)."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["A method of claim 1 wherein said MGF polypeptide comprises an amino acid sequence of 80% or greater identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, and 6."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["A method of treating a damaged nerve of the peripheral nervous system,
said treatment comprising administering to a subject comprising said nerve an effective non-toxic amount of an MGF (mechano-growth factor) polypeptide having the ability to reduce motoneurone loss by 20% or greater in response to nerve avulsion,
said administration comprising delivering said MGF polypeptide to the site of said damage;
said MGF polypeptide comprising at least one sequence selected from the group consisting of:
(a) an amino acid sequence comprising a sequence encoded by exons 4-5-6 of a mammalian MGF; and
(b) an amino acid sequence having 80% or greater sequence identity, over the sequence encoded by exons 4-5-6, to an amino acid sequence of (a)."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["A method of claim 13 wherein said MGF polypeptide is administered to said subject at a site of said damaged nerve by means of a conduit placed around the damaged nerve."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["A method of claim 14 wherein the conduit comprises Poly-3-hydroxy-butyrate (PHB)."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["A method of claim 14 wherein said conduit comprises at least one of collagen and silicone."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["A method of claim 14 wherein the damaged nerve was severed."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["A method of claim 13 wherein the damaged nerve was severed."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["A method of claim 13 wherein the MGF polypeptide is unglycosylated."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["A method of claim 13 wherein said MGF polypeptide comprises an amino acid so sequence selected from the group consisting of amino acids 26-110 of SEQ ID NO:2, amino acids 26-111 of SEQ ID NO:4, and amino acids 26-111 of SEQ ID NO:6."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["A method of claim 13 wherein said MGF polypeptide comprises an amino acid sequence which has 90% or greater sequence identity, over the sequence encoded by exons 4-5-6, with a sequence of (a)."],"number":21,"annotation":false,"claim":true,"title":false},{"lines":["A method of claim 13 wherein said MGP polypeptide comprises an amino acid sequence which has 80% or greater sequence identity with an amino acid sequence selected from the group consisting of amino acids 26-110 of SEQ ID NO:2, amino acids 26-111 of SEQ ID NO:4, and amino acids 26-111 of SEQ ID NO:6."],"number":22,"annotation":false,"claim":true,"title":false},{"lines":["A method of claim 13 wherein said MGF polypeptide comprises an amino acid so once which has 90% or greater sequence identity with an amino acid sequence selected from the group consisting of amino acids 26-110 of SEQ ID NO:2, amino acids 26-111 of SEQ ID NO:4, and amino acids 26-111 of SEQ ID NO:6."],"number":23,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}